Product logins

Find logins to all Clarivate products below.


Insomnia | Treatment Algorithms: Claims Data Analysis | US | 2021

Insomnia is a prevalent sleep disorder characterized by daytime dysfunction as a result of one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider multiple factors when selecting an appropriate therapeutic. The primary goal of treatment is to improve patients’ quality of sleep, with minimal next-day side effects. Although generics are entrenched in the insomnia treatment algorithm, new therapies have launched in the U.S. market, such as the dual orexin receptor antagonists Belsomra (Merck) and Dayvigo (Eisai), and the pipeline is becoming increasingly active.

Questions Answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed insomnia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed insomnia patients?
  • How have Belsomra and Dayvigo been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of insomnia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of insomnia patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Content Highlights

Geographies: United States.

Real-world data: Longitudinal patient-level claims data analysis.

Key drugs covered: Belsomra, Dayvigo, zolpidem IR, zolpidem CR, eszopiclone, trazodone, Rozerem, ramelteon, zaleplon, doxepin, BZDs.

Product Description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Solution Enhancement

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Related Market Assessment Reports

Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…
Report
Psoriatic Arthritis – Unmet Need – Unmet Need – Psoriatic Arthritis (US/EU)
The psoriatic arthritis (PsA) therapy market is on a growth trajectory, fueled by the disease’s increasing prevalence, innovative treatment options, and heightened patient awareness. TNF-alpha…
Report
Pulmonary Hypertension – Current Treatment – Current Treatment: Physician Insights – Pulmonary Arterial Hypertension (US)
Pulmonary arterial hypertension (PAH) treatment in the United States is undergoing notable shifts as physicians increasingly adopt guidelinealigned early combination therapy, driving steady use of…
Report
Male Hypogonadism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Male Hypogonadism (US)
Male hypogonadism (low testosterone, or low T) is a condition characterized by impaired spermatogenesis and low serum testosterone. Most cases are secondary, driven by aging or comorbidities (e.g…
Report
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
The treatment of early Alzheimer’s disease (AD) is being transformed by the launches of Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), and additional disease-…